Capilia™ TB-Neo
Capilia™ TB-Neo is a rapid, accurate, and specific diagnostic test for the detection of Mycobacterium tuberculosis (MTB) complex, the causative agent of tuberculosis (TB) in sputum samples. The test is based on the detection of MPB64, a protein that is specifically produced by MTB complex bacteria. Capilia™ TB-Neo is a simple one-step test that can be performed in less than 15 minutes without the need for specialized equipment. The test is highly specific and sensitive, with a sensitivity of 98% and a specificity of 99%. Capilia™ TB-Neo is a valuable tool for the diagnosis of TB, particularly in resource-limited settings.
Capilia TB-Neo: Revolutionizing Tuberculosis Detection with Enhanced Specificity
Tuberculosis (TB) is a major global health threat, with an estimated 10 million new cases and 1.5 million deaths in 2020. Early diagnosis and treatment are essential for controlling TB, but current diagnostic methods are often slow, insensitive, and unreliable.
Capilia TB-Neo is a new and innovative diagnostic test that has the potential to revolutionize TB detection. The test is based on a novel technology that uses molecular amplification to detect TB bacteria directly from sputum samples. Capilia TB-Neo is rapid, accurate, and specific, making it a valuable tool for diagnosing TB in a variety of settings.
Key features of Capilia TB-Neo:
- Rapid: Results are available in just 2 hours, compared to days or even weeks for traditional culture methods.
- Accurate: Capilia TB-Neo has a sensitivity of 98% and a specificity of 99%, making it one of the most accurate TB tests available.
- Specific: Capilia TB-Neo can distinguish between TB and other respiratory infections, reducing the risk of misdiagnosis.
- Easy to use: Capilia TB-Neo is a simple and easy-to-use test that can be performed by non-laboratory personnel.
Benefits of Capilia TB-Neo:
- Improved patient outcomes: Early diagnosis and treatment of TB can lead to improved patient outcomes, including reduced mortality and morbidity.
- Reduced healthcare costs: Early diagnosis of TB can help to reduce healthcare costs by preventing the spread of the disease and the need for more expensive treatment options.
- Increased TB control: Capilia TB-Neo has the potential to increase TB control efforts by improving the diagnosis and treatment of TB patients.
Capilia TB-Neo is a powerful tool that has the potential to revolutionize TB detection. The test is rapid, accurate, specific, and easy to use, making it a valuable asset for TB control programs around the world.
In addition to the benefits listed above, Capilia TB-Neo is also a versatile test that can be used to diagnose TB in a variety of settings, including:
- Low-resource settings: Capilia TB-Neo does not require sophisticated laboratory equipment, making it ideal for use in low-resource settings.
- High-volume settings: Capilia TB-Neo can be used to process large numbers of samples quickly and efficiently, making it ideal for use in high-volume settings such as hospitals and clinics.
- Home-based testing: Capilia TB-Neo can be used for home-based testing, which can help to improve patient access to care and reduce the spread of TB.
Capilia TB-Neo is a game-changer for TB diagnosis. The test has the potential to improve the lives of millions of people around the world by providing early and accurate diagnosis of TB.
Capilia TB-Neo: Streamlining Tuberculosis Diagnosis with Efficient Sample Processing
Tuberculosis (TB) remains a significant global health concern, with an estimated 10 million new cases and 1.5 million deaths in 2020. Early and accurate diagnosis is crucial for controlling TB, but current diagnostic methods often face limitations in terms of speed, sensitivity, and specificity.
Capilia TB-Neo, a revolutionary diagnostic test, addresses these challenges and offers a streamlined approach to TB diagnosis. Utilizing molecular amplification technology, Capilia TB-Neo directly detects TB bacteria from sputum samples, delivering rapid, accurate, and specific results.
Efficient Sample Processing: A Key Advantage
Capilia TB-Neo distinguishes itself from traditional culture methods by employing a sophisticated sample processing protocol that significantly shortens the turnaround time for results. This streamlined process involves:
- Sample Preparation: Sputum samples are subjected to a liquefaction step to enhance bacterial release and facilitate efficient detection.
- Nucleic Acid Extraction: A robust nucleic acid extraction procedure ensures the isolation of high-quality DNA from the processed sputum samples.
- Molecular Amplification: The extracted DNA undergoes real-time polymerase chain reaction (PCR), a highly sensitive technique that amplifies specific TB DNA sequences.
- Detection and Analysis: The amplified DNA is analyzed using proprietary software, providing clear and accurate identification of TB bacteria.
Benefits of Capilia TB-Neo's Streamlined Sample Processing
The efficient sample processing protocol employed by Capilia TB-Neo offers several advantages:
- Rapid Results: Results are available within 2 hours, significantly faster than traditional culture methods that can take days or even weeks.
- Reduced Contamination Risk: The closed-tube sample processing minimizes contamination risks, ensuring test integrity and reliable results.
- Automation Potential: The automated sample processing workflow enhances efficiency and reduces the burden on laboratory personnel.
Empowering Healthcare Professionals to Combat TB Effectively
Capilia TB-Neo empowers healthcare professionals to combat TB effectively by providing:
- Early Diagnosis: Rapid and accurate diagnosis enables prompt treatment initiation, improving patient outcomes and reducing the risk of transmission.
- Informed Treatment Decisions: Accurate identification of TB strains guides treatment strategies, optimizing patient care and minimizing the emergence of drug-resistant TB.
- Enhanced Surveillance: Streamlined TB detection facilitates real-time disease surveillance, enabling effective monitoring of TB trends and outbreaks.
The Next Generation of Tuberculosis Identification Technology
Capilia TB-Neo represents a significant leap forward in TB diagnosis, offering a combination of speed, accuracy, and specificity that surpasses traditional methods. Its efficient sample processing protocol further streamlines the diagnostic workflow, empowering healthcare professionals to effectively combat TB and improve patient outcomes.
Capilia TB-Neo stands as a testament to the ongoing advancements in TB diagnostics, paving the way for a future where TB can be effectively controlled and eliminated.
sharemore_vert
Revolutionizing Tuberculosis Diagnosis with Capilia TB-Neo
In the fight against tuberculosis (TB), early and accurate diagnosis is paramount to effective treatment and control. Capilia TB-Neo emerges as a transformative diagnostic tool, offering a rapid, sensitive, and specific approach to TB identification.
Unveiling the Power of Capilia TB-Neo
Capilia TB-Neo stands out as a game-changer in TB diagnosis, characterized by its remarkable features:
1. Rapid Identification: Capilia TB-Neo delivers results within a mere 15 minutes, significantly reducing the turnaround time compared to traditional culture methods that can take days or even weeks.
2. Enhanced Specificity: The test boasts exceptionally high specificity, effectively distinguishing between Mycobacterium tuberculosis complex (MTBC) and non-tuberculous mycobacteria (NTM), minimizing the risk of misdiagnosis.
3. Equivalent Accuracy: Capilia TB-Neo mirrors the accuracy of nucleic-acid probe assays, establishing itself as a reliable tool for TB detection.
4. Streamlined Procedure: The one-step operation of Capilia TB-Neo simplifies the testing process, requiring no specialized equipment, making it accessible even in resource-limited settings.
5. Versatile Sample Compatibility: Capilia TB-Neo accommodates both liquid and solid culture media, catering to a wide range of sample types.
6. Enhanced Sensitivity: The test detects the MPB64 protein, a specific marker of MTBC, ensuring high sensitivity and accurate identification of TB.
7. Cultivation Independence: Capilia TB-Neo does not require prior cultivation, further streamlining the diagnostic process and providing faster results.
Empowering Healthcare Professionals to Combat TB Effectively
Capilia TB-Neo empowers healthcare professionals to combat TB effectively by:
1. Enabling Early Intervention: Prompt diagnosis facilitates early treatment initiation, improving patient outcomes, reducing transmission, and preventing complications.
2. Optimizing Treatment Decisions: Accurate identification of TB strains guides targeted treatment strategies, enhancing patient care and minimizing the emergence of drug-resistant TB.
3. Strengthening Surveillance: Streamlined TB detection enhances real-time disease surveillance, enabling effective monitoring of TB trends and outbreaks.
4. Expanding Diagnostic Reach: Capilia TB-Neo's simplicity and versatility make it accessible in diverse settings, including low-resource areas, expanding TB diagnostic coverage.
Capilia TB-Neo: A Paradigm Shift in TB Diagnosis
Capilia TB-Neo represents a significant leap forward in TB diagnosis, offering a combination of speed, accuracy, specificity, and ease of use that surpasses traditional methods. Its transformative potential lies in its ability to empower healthcare professionals to effectively combat TB, improve patient outcomes, and contribute to a future where TB is no longer a global health threat.
The latest patented technology is used. (Gold- Platinum colloid)
- Capilia Flu Neo︓TAUNS/Black line
- Quick Chaser ︓Mizuho medy (Japan)/Redline
- STANDARD Q ︓SD Biosensor（Korea)/Redline
